Stanley Fisher, MD, FANA, FAAN has been serving as a Vice President and Head of Medical Affairs, Specialty Pharma Division of Amneal Pharmaceuticals for the last 5 years and was instrumental in bringing IPX203 to US market. He is also currently holding adjunct appointments at the Weill Cornell Medical College and Rutgers New Jersey Medical School Departments of Neurology. He specializes in Movement Disorders and Neurological Rehabilitation.
Prior to joining Amneal in 2019, he has served as a Co-Director of Saint Luke Marion Bloch Neuroscience Institute (SLMBNI) in Kansas City, Missouri for more than 4 years. Dr. Fisher was a Chair of the Division of Neuroscience and Chief of the Department of Neurology there as well. Dr. Fisher lead SLMBNI to become a top 50 neuroscience program in the country by US News and World report for the last three years as a chair. He has established new neurology residency program, reinvigorated research enterprise, and created 9 centers of excellence within the division. He held a faculty appointment at the rank of Professor in the Department of Neurology and a secondary appointment in the Department of Psychiatry at the UMKC School of Medicine. He also was appointed as Edward T. Matheny, JR/Missouri Endowed Chair in Neurosciences, with the mandate to define the future of neuroscience through innovation, research and state-of-the art clinical care as well as the management of an academic program of neurosciences.
Dr. Fisher is a Fellow of American Academy of Neurology (AAN) and of American Neurological Association (ANA). He was instrumental in creating and has served first as Vice President and then as a President of the Kansas City Clinical Neuroscience Society as well as a board member of Missouri/Kansas Neurological Society. He had in the past served as Vice Chair of the Neural Repair and Rehabilitation Section of AAN.
